Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Grant Verstandig
AddedMar 31, 2024
UpdatedJun 28, 2026
Grant Verstandig

Grant Verstandig

Board Member, Red Cell Partners

CrunchbaseLinkedIn

Grant Verstandig's Career

Red Cell Partners
Red Cell Partners

Washington, D.C., DC, US

Board Member· Board
Zephyr AI
Zephyr AI

Dallas, TX, US

Board Member· Board
Envisagenics
Envisagenics

New York City, NY, US

Board Member· Board
Epirus
Epirus

Hawthorne, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Grant Verstandig's Career

Red Cell Partners
Red Cell Partners
Investment FirmInvestment Firm572020Washington, D.C., DC, US
Board Member· Board

Recent news

Defcon AI closes $44M seed round to solve a problem of ‘maximum complexity’: Military logisticsTechCrunch · 2024

Similar to Red Cell Partners

Reddy Capital PartnersReddy Capital PartnersLos Angeles, CA, USest. 2007Reddy Capital PartnersLos Angeles, CA, US · est. 2007

Reddy Capital Partners LLC: A US-based venture capital firm specializing in early-stage financing.

Investment Firm5
Red Sea VenturesRed Sea VenturesNew York City, NY, USest. 2011Red Sea VenturesNew York City, NY, US · est. 2011

Red Sea Ventures LLC: A US-based venture capital firm investing in early-stage tech companies.

Investment Firm7
RedBird Capital PartnersRedBird Capital PartnersNew York City, NY, USest. 2013RedBird Capital PartnersNew York City, NY, US · est. 2013

RedBird Capital Partners: A private firm providing flexible, long-term capital for business growth.

Investment Firm75
Cell Rising CapitalCell Rising CapitalRhode Island, USest. 2020Cell Rising CapitalRhode Island, US · est. 2020

Investing in cutting-edge tech and AI, Cell Rising Capital is a venture capital fund.

Investment Firm3
Zephyr AI
Zephyr AI
Seed$18.5M472020Dallas, TX, US
Board Member· Board

Leadership at Zephyr AI

Justin StebbingJustin StebbingBoard Member
Yisroel BrumerYisroel BrumerBoard Member
David L. Morgan IIDavid L. Morgan IICEO

Similar to Zephyr AI

Pathos AIPathos AIChicago, IL, USDrug Discoveryest. 2020Pathos AIChicago, IL, US · est. 2020

Pathos: AI and big data-driven platform streamlining end-to-end drug discovery and development.

Series B · $20M3
InsitroInsitroSouth San Francisco, CA, USDrug Discoveryest. 2018InsitroSouth San Francisco, CA, US · est. 2018

Insitro: Leveraging machine learning for data-driven drug discovery and development.

Series C · $643M295
TandemAITandemAINew York City, NY, USDrug Discoveryest. 2021TandemAINew York City, NY, US · est. 2021

TandemAI: An advanced AI company revolutionizing drug discovery.

Series A · $60M46
Envisagenics
Envisagenics
Series A$27.1M472014New York City, NY, US
Board Member· Board

Leadership at Envisagenics

Sudhir AgrawalSudhir AgrawalBoard Member
Martin AkermanMartin AkermanCo-Founder
Maria Luisa PinedaMaria Luisa PinedaCo-Founder

Similar to Envisagenics

Enveda BiosciencesEnveda BiosciencesBoulder, CO, USDrug Discoveryest. 2019Enveda BiosciencesBoulder, CO, US · est. 2019

Enveda Biosciences, a Boulder-based biotech firm, innovatively transforms plant molecules into drugs using advanced AI.

Series B · $174.9M175
SrnalyticsSrnalyticsWaltham, MA, USDrug Discoveryest. 2016SrnalyticsWaltham, MA, US · est. 2016

sRNAlytics: Pioneering small RNA research with technology and services for accelerated drug discovery.

Seed · $2.5M9
Atomic AIAtomic AISouth San Francisco, CA, USDrug Discoveryest. 2021Atomic AISouth San Francisco, CA, US · est. 2021

Atomic AI: Pioneering molecule and medicine design through AI and structural biology fusion.

Series A · $42M38
OwkinOwkinNew York City, NY, USAI Drug Discovery, Diagnosticsest. 2016OwkinNew York City, NY, US · est. 2016

NYC-based Owkin, Inc. leverages machine learning for predictive analytics in biotech, serving global pharma.

Series B · $304.1M441
Epirus
Epirus
Series C$287.6M2002018Hawthorne, CA, US
Board Member· Board

Recent news

Epirus Receives $43.5 Million Contract from U.S. Army for IFPC-HPM Generation II SystemsEpirus · 2025
Epirus Closes $250M Series D to Hyperscale Leonidas Production Capability for Critical Asset ProtectionPR Newswire · 2025
Defense startup Epirus in talks to raise over $150M, potentially cutting valuationTechCrunch · 2025

Leadership at Epirus

Bo MarrBo MarrCo-Founder
Max MednikMax MednikCo-Founder
Geoff LewisGeoff LewisBoard Member
Joe LonsdaleJoe LonsdaleBoard Member
Kenneth BedingfieldKenneth BedingfieldCEO

Grant Verstandig's Co-Investors

James HardimanJames HardimanCo-invested · nTopology Series BAvidan RossAvidan RossCo-invested · nTopology Series BGreg SchroyGreg SchroyCo-invested · nTopology Convertible NoteColin CarrierColin CarrierCo-invested · nTopology Convertible NoteBob PaskerBob PaskerCo-invested · nTopology Convertible Note

Grant Verstandig's Similar Executives & Operators

Nugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakChi-hyung SongChi-hyung SongBoard Member · DunamuHaeil YiHaeil YiCo-Founder · Dunamu

People Similar to Grant Verstandig

Richard KlausnerRichard KlausnerFounder · Pathwork DiagnosticsGeoff RehnertGeoff RehnertCo-Founder · Audax GroupAdam HandfingerAdam HandfingerBoard Member · Document CrunchRon GeratyRon GeratyBoard Member · PodimetricsArun GuptaArun GuptaBoard Member · Big HealthScott JensScott JensBoard Member · ThirdSpace